Synapse

← Hagop M. Kantarjian

Papers by Hagop M. Kantarjian

Page 1 · newest first

  1. Acute lymphocytic leukaemiaThe Lancet · 2025
  2. An all-oral triplet regimen (decitabine/cedazuridine, venetoclax, and gilteritinib) for newly diagnosed and relapsed/refractory FLT3-mutated AML and high-risk MDSBlood Cancer Journal · 2026
  3. Dose optimization of single-agent inotuzumab ozogamicin in adults with relapsed/refractory acute lymphoblastic leukemiaLeukemia & lymphoma/Leukemia and lymphoma · 2026
  4. Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemiaCancer · 2026
  5. Treatment of adult acute lymphoblastic leukemia—a therapeutic revolution in the makingBlood Cancer Journal · 2026
  6. Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trialLeukemia · 2026
  7. Results of second‐line therapy in adult Philadelphia chromosome‐positive acute lymphoblastic leukemiaCancer · 2026
  8. Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemiaLeukemia · 2026
  9. Predictors of survival in adults with B-cell acute lymphoblastic leukemia treated with blinatumomab and/or inotuzumab ozogamicin in first salvageLeukemia · 2026
  10. Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase IILeukemia · 2026
  11. Adult acute lymphoblastic leukemia: incorporation of recent advances into current treatment strategiesBlood Cancer Journal · 2026
  12. Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemiaBlood Cancer Journal · 2026
  13. Investigational Clinical Trial Agents versus Conventional Second Salvage Therapies in Patients with Relapsed/Refractory Acute Myeloid LeukemiaClinical Cancer Research · 2026
  14. The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE)Journal of Clinical Oncology · 2026
  15. Preliminary data from the ongoing Phase 1 study of the menin-MLL inhibitor enzomenib (DSP-5336) in combination with venetoclax and azacitidine in patients with relapsed or refractory Acute Myeloid LeukemiaBlood · 2025
  16. Multimodal assessment of chronic myelomonocytic leukemia with extramedullary involvement reveals RAS pathway activation, adverse outcomes and epithelial-mesenchymal transitionBlood · 2025
  17. RUNX1 mutations define a high-risk biological subset of chronic myelomonocytic leukemia and cooperate with ASXL1 mutations to drive leukemic transformationBlood · 2025
  18. Impact of uncontrolled hyperglycemia during induction chemotherapy on response and survival outcomes in patients with adult B-cell acute lymphoblastic leukemia (B-ALL) on HCVAD-based regimensBlood · 2025
  19. Outcomes of hypomethylating agent failure in patients with myelodysplastic syndromesBlood · 2025
  20. A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemiasJournal of Hematology & Oncology · 2025
  21. Cladribine, high-dose cytarabine, plus gemtuzumab ozogamicin (CLAG-GO) as frontline intensive therapy for fit patients with core-binding factor acute myeloid leukemiaLeukemia & lymphoma/Leukemia and lymphoma · 2025
  22. Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemiaBlood Neoplasia · 2025
  23. Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALLBlood Cancer Journal · 2025
  24. A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lensCancer · 2025
  25. Cladribine and venetoclax combined with alemtuzumab in patients with relapsed/refractory T-cell prolymphocytic leukemiaLeukemia & lymphoma/Leukemia and lymphoma · 2025
  26. MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemiaBritish Journal of Haematology · 2025
  27. Combination Strategies with Menin Inhibitors for Acute LeukemiaBlood Cancer Discovery · 2025
  28. Cytomolecular Mechanisms of Relapse and Post‐Relapse Outcomes After Frontline FLT3 Inhibitor‐Based Therapy in FLT3 ‐Mutated AMLAmerican Journal of Hematology · 2025
  29. Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based TherapiesAmerican Journal of Hematology · 2025
  30. Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutation.2025
  31. Outcomes and patterns of relapse with ponatinib-based therapy in patients with chronic myeloid leukemia in myeloid blast phase.2025
  32. Contemporary outcomes of octa‐nonagenarians with newly diagnosed acute myeloid leukemiaCancer · 2025
  33. Mini-hyper-CVD plus venetoclax and navitoclax for relapsed/refractory acute lymphoblastic leukemiaBlood Advances · 2025
  34. Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies2025
  35. Incorporation of Immunotherapy Into Adult B-Cell Acute Lymphoblastic Leukemia TherapyJournal of the National Comprehensive Cancer Network · 2025
  36. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemiaLeukemia · 2025
  37. Management of chronic myeloid leukemia in 2025Cancer · 2025
  38. Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AMLHemaSphere · 2025
  39. Clonal evolution of hematopoietic stem cells after autologous stem cell transplantationNature Genetics · 2025
  40. Managing BPDCN in the context of severe hyperbilirubinemia: a case studyLeukemia & lymphoma/Leukemia and lymphoma · 2025
  41. Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AMLJournal of Clinical Oncology · 2025
  42. A Phase 2 Trial of CPX‐351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid LeukemiaAmerican Journal of Hematology · 2025
  43. Adult Acute Lymphoblastic Leukemia: 2025 Update on Diagnosis, Therapy, and MonitoringAmerican Journal of Hematology · 2025
  44. Treatment of Older Patients With ALLAmerican Society of Clinical Oncology Educational Book · 2025
  45. The evolving therapeutic revolution in adult acute lymphoblastic leukemiaCancer · 2025
  46. Management of Adult Acute Lymphoblastic LeukemiaJAMA Oncology · 2025
  47. Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patientsBlood Cancer Journal · 2025
  48. Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative AnalysisClinical Cancer Research · 2025
  49. Olverembatinib in chronic myeloid leukemia—Review of historical development, current status, and future researchCancer · 2025
  50. Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single‐center, single‐arm, phase 2 trialCancer · 2025